Last 12 months
Inside the activity.
1 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 1 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 23, 2025 Filed Dec 29, 2025 21:23 UTC |
Thompson Tommy GDirector
|
PurchaseCommon Stock | 8,400 | $1.67 | $14,030.52 |
DisclosureSEC source: 0000905148-25-004488 · form4.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,179 Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:18 UTC |
Thompson Tommy GDirector
|
GrantRestricted Stock Units · Derivative | 8,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-003785 · form4.xml · derivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:17 UTC |
Collins Cooper C.Director
|
GrantRestricted Stock Units · Derivative | 8,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-003783 · form4.xml · derivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:17 UTC |
Naughton Gail KDirector
|
GrantRestricted Stock Units · Derivative | 8,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-003784 · form4.xml · derivative · entry 1 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:16 UTC |
Walker Marlan DChief Executive Officer
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 67,492 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0000905148-25-003782 · form4.xml · derivative · entry 1 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,492 Underlying: Common Stock · 67,492 shares Expires 2035-11-03 F1 · derivative.exercise_date: Underlying shares each vested on November 3, 2025. Read SEC document |
| April 14, 2025 Filed Apr 15, 2025 11:59 UTC |
Thompson Tommy GDirector
|
PurchaseCommon Stock | 325 | $1.00 | $325.59 |
DisclosureSEC source: 0000905148-25-001216 · form4.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,779 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices of $0.99 through $1.05, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth. Read SEC document |
| April 14, 2025 Filed Apr 15, 2025 11:59 UTC |
Walker Marlan DChief Executive Officer
|
PurchaseCommon Stock | 490 | $1.00 | $489.27 |
DisclosureSEC source: 0000905148-25-001215 · form4.xml · nonDerivative · entry 1 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,639 Read SEC document |
| April 10, 2025 Filed Apr 10, 2025 20:29 UTC |
Walker Marlan DChief Executive Officer
|
PurchaseCommon Stock | 1,167 | $0.86 | $1,000.35 |
DisclosureSEC source: 0000905148-25-001190 · form4.xml · nonDerivative · entry 2 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,149 Read SEC document |
| April 09, 2025 Filed Apr 10, 2025 20:29 UTC |
Walker Marlan DChief Executive Officer
|
PurchaseCommon Stock | 1,136 | $0.87 | $993.66 |
DisclosureSEC source: 0000905148-25-001190 · form4.xml · nonDerivative · entry 1 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,982 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices of $0.8741 through $0.88, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:08 UTC |
Collins Cooper C.Director
|
Exercise / conversionRestricted Stock Units · Derivative | 8,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000740 · form4.xml · derivative · entry 2 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 8,500 shares of common stock of the issuer in settlement of RSUs, which vested on July 17, 2024. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 8,500 shares of common stock of the issuer in settlement of RSUs, which vested on July 17, 2024. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:08 UTC |
Collins Cooper C.Director
|
Exercise / conversionCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000740 · form4.xml · nonDerivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:07 UTC |
Naughton Gail KDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 8,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000739 · form4.xml · derivative · entry 2 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 8,500 shares of common stock of the issuer in settlement of RSUs, which vested on July 17, 2024. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 8,500 shares of common stock of the issuer in settlement of RSUs, which vested on July 17, 2024. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:07 UTC |
Naughton Gail KDirector
|
Exercise / conversionCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000739 · form4.xml · nonDerivative · entry 1 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:07 UTC |
Walker Marlan DChief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,733 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000737 · form4.xml · derivative · entry 8 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,733 Underlying: Common Stock · 1,733 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025. On February 18, 2025, the reporting person received 1,733 shares of common stock of the issuer in settlement of RSUs, which vested on March 23, 2024. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025. On February 18, 2025, the reporting person received 1,733 shares of common stock of the issuer in settlement of RSUs, which vested on March 23, 2024. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:07 UTC |
Walker Marlan DChief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 770 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000737 · form4.xml · derivative · entry 7 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 770 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 770 shares of common stock of the issuer in settlement of RSUs, which vested on September 29, 2024. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 770 shares of common stock of the issuer in settlement of RSUs, which vested on September 29, 2024. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:07 UTC |
Walker Marlan DChief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 2,311 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000737 · form4.xml · derivative · entry 6 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,311 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 2,311 shares of common stock of the issuer in settlement of RSUs, which vested on July 1, 2024. F2 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 2,311 shares of common stock of the issuer in settlement of RSUs, which vested on July 1, 2024. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:07 UTC |
Walker Marlan DChief Executive Officer
|
Exercise / conversionPerformance Stock Units · Derivative | 3,467 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000737 · form4.xml · derivative · entry 5 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each performance stock unit ("PSU") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 3,467 shares of common stock of the issuer in settlement of PSUs. F1 · derivative.expiration_date: Each performance stock unit ("PSU") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 3,467 shares of common stock of the issuer in settlement of PSUs. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:07 UTC |
Walker Marlan DChief Executive Officer
|
Exercise / conversionCommon Stock | 1,733 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000737 · form4.xml · nonDerivative · entry 4 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:07 UTC |
Walker Marlan DChief Executive Officer
|
Exercise / conversionCommon Stock | 770 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000737 · form4.xml · nonDerivative · entry 3 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,113 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:07 UTC |
Walker Marlan DChief Executive Officer
|
Exercise / conversionCommon Stock | 2,311 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000737 · form4.xml · nonDerivative · entry 2 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:07 UTC |
Walker Marlan DChief Executive Officer
|
Exercise / conversionCommon Stock | 3,467 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000737 · form4.xml · nonDerivative · entry 1 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:07 UTC |
Thompson Tommy GDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 8,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000738 · form4.xml · derivative · entry 4 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 8,500 shares of common stock of the issuer in settlement of RSUs, which vested on July 17, 2024. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 8,500 shares of common stock of the issuer in settlement of RSUs, which vested on July 17, 2024. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:07 UTC |
Thompson Tommy GDirector
|
Exercise / conversionCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000738 · form4.xml · nonDerivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,454 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 22, 2024 Filed Aug 26, 2024 21:40 UTC |
Collins Cooper C.Director
|
PurchaseCommon Stock | 4,094 | $1.73 | $7,099.00 |
DisclosureSEC source: 0000905148-24-002363 · form4.xml · nonDerivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,016 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices of $1.69 through $1.75, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 22:18 UTC |
Collins Cooper C.Director
|
PurchaseCommon Stock | 1,200 | $1.70 | $2,038.56 |
DisclosureSEC source: 0000905148-24-002340 · form4.xml · nonDerivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,922 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices of $1.685 through $1.70, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth. Read SEC document |
| December 07, 2023 Filed Dec 7, 2023 21:51 UTC |
Walker Marlan DChief Executive Officer
|
SaleCommon Stock | 4,550 | $2.24 | $10,187.45 |
DisclosureSEC source: 0001209191-23-057725 · doc4.xml · nonDerivative · entry 3 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,565 F1 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $2.15 through $2.31, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 21:51 UTC |
Walker Marlan DChief Executive Officer
|
SaleCommon Stock | 14,500 | $2.31 | $33,496.45 |
DisclosureSEC source: 0001209191-23-057725 · doc4.xml · nonDerivative · entry 2 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,115 F1 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $2.22 through $2.48, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth. Read SEC document |
| December 05, 2023 Filed Dec 7, 2023 21:51 UTC |
Walker Marlan DChief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 70,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-057725 · doc4.xml · derivative · entry 4 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on June 30, 2023. F4 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on June 30, 2023. Read SEC document |
| December 05, 2023 Filed Dec 7, 2023 21:51 UTC |
Walker Marlan DChief Executive Officer
|
Exercise / conversionCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-057725 · doc4.xml · nonDerivative · entry 1 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 14:27 UTC |
Rubric Capital Management LPDirector · 10% owner · See Remarks.
Rosen David Efraim10% owner
|
GrantCommon Stock, par value $0.001 per share ("Common Stock") | 877,192 | $2.28 | $1,999,997.76 |
DisclosureSEC source: 0001104659-23-119331 · tm2330971-1_4seq1.xml · nonDerivative · entry 1 Rubric Capital Management LP · CIK 0001687509 · Director · 10% owner · See Remarks. Rosen David Efraim · CIK 0001898677 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,946,908 F1 · price: The Common Stock was purchased in connection with a Subscription Agreement entered into as of May 1, 2023 between the Issuer and Rubric Capital, as described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023. F2 · ownership.nature: This Form 4 is filed by Rubric Capital Management LP ("Rubric Capital") and Mr. David Rosen, with respect to the securities held by certain funds and/or accounts (collectively, the "Rubric Vehicles"). Rubric Capital serves as the investment adviser to the Rubric Vehicles. Mr. David Rosen serves as the Managing Member of Rubric Capital Management GP, LLC, the general partner of Rubric Capital. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 17, 2023 Filed Aug 21, 2023 20:22 UTC |
ZIEGLER JOSEPHPrincipal Financial Officer
|
GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046702 · doc4.xml · nonDerivative · entry 1 ZIEGLER JOSEPH · CIK 0001979286 · Principal Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 F1 · shares: These shares of common stock of the Issuer are to be acquired upon the vesting of restricted stock units ("RSUs") granted to the Reporting Person. The RSUs shall fully vest on the earlier of August 17, 2024 or a Change in Control of the Issuer (as defined in the Issuer's 2019 Stock Incentive Plan). Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 21:29 UTC |
Thompson Tommy GDirector
|
GrantRestricted Stock Units · Derivative | 8,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-042767 · doc4.xml · derivative · entry 1 Thompson Tommy G · CIK 0001324863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on July 17, 2024. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on July 17, 2024. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 21:28 UTC |
Naughton Gail KDirector
|
GrantRestricted Stock Unit · Derivative | 8,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-042765 · doc4.xml · derivative · entry 1 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on July 17, 2024. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on July 17, 2024. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 21:27 UTC |
Collins Cooper C.Director
|
GrantRestricted Stock Units · Derivative | 8,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-042763 · doc4.xml · derivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on July 17, 2024. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on July 17, 2024. Read SEC document |
| June 28, 2023 Filed Jun 29, 2023 21:21 UTC |
Rubric Capital Management LPDirector · 10% owner · See Remarks
Rosen David EfraimDirector · 10% owner · See Remarks
|
GrantCommon Stock, par value $0.001 per share ("Common Stock") | 312,525 | $3.68 | $1,149,998.24 |
DisclosureSEC source: 0001104659-23-076387 · tm2320269-1_4seq1.xml · nonDerivative · entry 1 Rubric Capital Management LP · CIK 0001687509 · Director · 10% owner · See Remarks Rosen David Efraim · CIK 0001898677 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,069,716 F1 · price: The Common Stock was purchased in connection with a Subscription Agreement entered into as of May 1, 2023 between the Issuer and Rubric Capital, as described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023. F2 · ownership.nature: This Form 4 is filed by Rubric Capital Management LP ("Rubric Capital") and Mr. David Rosen, with respect to the securities held by certain funds and/or accounts (collectively, the "Rubric Vehicles"). Rubric Capital serves as the investment adviser to the Rubric Vehicles. Mr. David Rosen serves as the Managing Member of Rubric Capital Management GP, LLC, the general partner of Rubric Capital. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| April 26, 2023 Filed May 4, 2023 20:38 UTC Amendment |
Walker Marlan DChief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,734 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-027361 · doc4a.xml · derivative · entry 5 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,466 Underlying: Common Stock · 1,734 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025. F4 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025. Read SEC document |
| April 26, 2023 Filed May 4, 2023 20:38 UTC Amendment |
Walker Marlan DChief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,010 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-027361 · doc4a.xml · derivative · entry 4 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in three equal installments annually, becoming fully vested on March 30, 2023. F3 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in three equal installments annually, becoming fully vested on March 30, 2023. Read SEC document |
| April 26, 2023 Filed May 4, 2023 20:38 UTC Amendment |
Walker Marlan DChief Executive Officer
|
SaleCommon Stock | 692 | $3.64 | $2,517.57 |
DisclosureSEC source: 0001209191-23-027361 · doc4a.xml · nonDerivative · entry 3 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,615 F2 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations. Read SEC document |
| April 26, 2023 Filed May 4, 2023 20:38 UTC Amendment |
Walker Marlan DChief Executive Officer
|
Exercise / conversionCommon Stock | 1,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-027361 · doc4a.xml · nonDerivative · entry 2 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The beneficially owned shares have been adjusted as the restricted stock units previously reported as settled on April 12, 2023 were not settled on that date. The restricted stock units settled on April 26, 2023. Read SEC document |
| April 26, 2023 Filed May 4, 2023 20:38 UTC Amendment |
Walker Marlan DChief Executive Officer
|
Exercise / conversionCommon Stock | 1,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-027361 · doc4a.xml · nonDerivative · entry 1 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The beneficially owned shares have been adjusted as the restricted stock units previously reported as settled on April 12, 2023 were not settled on that date. The restricted stock units settled on April 26, 2023. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 23:20 UTC |
Walker Marlan DChief Executive Officer
|
Exercise / conversionPerformance Stock Units · Derivative | 1,734 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024388 · doc4.xml · derivative · entry 9 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,466 Underlying: Common Stock · 1,734 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The vested performance stock units (PSUs) represent PSUs deemed by the compensation committee to be vested at target due to the change in the issuer's business model. The remaining PSUs vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023. One quarter of the initial PSUs were forfeited based on the failure of the issuer to achieve certain EBITDA milestones for the year ended December 31, 2021. Each PSU represents a contingent right to receive one share of common stock of the issuer. F6 · derivative.expiration_date: The vested performance stock units (PSUs) represent PSUs deemed by the compensation committee to be vested at target due to the change in the issuer's business model. The remaining PSUs vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023. One quarter of the initial PSUs were forfeited based on the failure of the issuer to achieve certain EBITDA milestones for the year ended December 31, 2021. Each PSU represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 23:20 UTC |
Walker Marlan DChief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,734 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024388 · doc4.xml · derivative · entry 8 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,466 Underlying: Common Stock · 1,734 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025. F5 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 23:20 UTC |
Walker Marlan DChief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,010 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024388 · doc4.xml · derivative · entry 7 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in three equal installments annually, becoming fully vested on March 30, 2023. F4 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in three equal installments annually, becoming fully vested on March 30, 2023. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 23:20 UTC |
Walker Marlan DChief Executive Officer
|
Exercise / conversionPerformance Stock Units · Derivative | 3,030 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024388 · doc4.xml · derivative · entry 6 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,030 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The performance stock units (PSUs) vested upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs would have been forfeited. Each PSU represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.expiration_date: The performance stock units (PSUs) vested upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs would have been forfeited. Each PSU represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 23:20 UTC |
Walker Marlan DChief Executive Officer
|
SaleCommon Stock | 1,170 | $3.65 | $4,275.53 |
DisclosureSEC source: 0001209191-23-024388 · doc4.xml · nonDerivative · entry 5 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,307 F1 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $3.63 through $3.71, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 23:20 UTC |
Walker Marlan DChief Executive Officer
|
Exercise / conversionCommon Stock | 1,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024388 · doc4.xml · nonDerivative · entry 4 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 23:20 UTC |
Walker Marlan DChief Executive Officer
|
Exercise / conversionCommon Stock | 1,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024388 · doc4.xml · nonDerivative · entry 3 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 23:20 UTC |
Walker Marlan DChief Executive Officer
|
Exercise / conversionCommon Stock | 1,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024388 · doc4.xml · nonDerivative · entry 2 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 23:20 UTC |
Walker Marlan DChief Executive Officer
|
Exercise / conversionCommon Stock | 3,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024388 · doc4.xml · nonDerivative · entry 1 Walker Marlan D · CIK 0001820187 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 23:17 UTC |
Donegan Michael CPrin. Fin. and Acctg. Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 50,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024386 · doc4.xml · derivative · entry 2 Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On April 12, 2023, the reporting person received 50,000 shares of issuer common stock in settlement of restricted stock units (RSUs). F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on March 31, 2023. F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on March 31, 2023. F2 · derivative.underlying_shares: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on March 31, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.